NERV - ミネルバ・ニュ―ロサイエンシズ (Minerva Neurosciences Inc) ミネルバ・ニュ―ロサイエンシズ

 NERVのチャート


 NERVの企業情報

symbol NERV
会社名 Minerva Neurosciences Inc (ミネルバ・ニュ―ロサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ミネルバ・ニューロサイエンス(Minerva Neurosciences Inc. )は臨床段階のバイオ医薬品会社である。同社は中枢神経系(CNS)疾患に患う患者を治療するために、製品候補のポートフォリオを開発・商品化する。同社の製品ポートフォリオは統合失調症の治療用MIN-101、不眠症およびうつ病障害(MDD)の治療用MIN-202、MDDの治療用MIN-117及びパーキンソン病の治療用MIN-301を含む。MIN-101は気分、認知、睡眠および不安の調節に関与する脳内の2つの受容体であるセロトニン受容体およびシグマ受容体を遮断する化合物である。MIN-117は5-ヒドロキシトリプタミンタイプ1A(5-HT1A)と呼ばれるセロトニン受容体の特定のサブタイプを遮断する。MIN-202は選択的オレキシン2受容体アンタゴニストである。MIN-301はパーキンソン病の治療のためのニューレグリン-1 1b1(NRG-1b1)タンパク質の可溶性組換え形態である。   ミネルバ・ニュ―ロサイエンシズは、米国のバイオ医薬品会社。中枢神経系(CNS)疾患の患者を治療するため、製品の開発、実用化に注力する。臨床段階にある主要な薬剤候補は、「MIN-101」や「MIN-117」など。統合失調症、大うつ病性障害、不眠症、パ―キンソン病の治療のため、治験薬の開発を行っている。   Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.
本社所在地 1601 Trapelo Road Suite 286 Waltham MA 02451 USA
代表者氏名 Remy Luthringer レミー・ライスリンガー
代表者役職名 Executive Chairman of the Board Chief Executive Officer
電話番号 +1 617-600-7373
設立年月日 39173
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 12人
url www.minervaneurosciences.com
nasdaq_url https://www.nasdaq.com/symbol/nerv
adr_tso
EBITDA EBITDA(百万ドル) -46.60467
終値(lastsale) 11.17
時価総額(marketcap) 433109411.31
時価総額 時価総額(百万ドル) 409.84480
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 302.75407
当期純利益 当期純利益(百万ドル) -45.44626
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Minerva Neurosciences Inc revenues was not reported. Net loss increased 22% to $24.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.57 to -$0.64.

 NERVのテクニカル分析


 NERVのニュース

   Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference  2020/09/02 12:30:00 GlobeNewswire
WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the…
   Back-to-School Without a Glitch: Arizona Virtual Academy Opens its Online Doors for the New School Year  2020/08/06 15:30:00 Business Wire
GLENDALE, Ariz.--(BUSINESS WIRE)--Arizona Virtual Academy (AZVA), a tuition-free full-time online public school, serving students in grades K-12 throughout the state, is ready to get back to work providing Arizona students with the safe and comprehensive education they need during these historic times. Students and teachers will open their laptops to log on and start the 2020-2021 school year Monday, August 10th. The first day of school comes as families across the state are frustrated and nerv
   Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates  2020/08/03 07:30:00 Benzinga
WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the …
   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   Minerva Neurosciences Opts Out of Agreement With Janssen for Seltorexant | MarketScreener  2020/07/01 12:57:01 MarketScreener
By Robb M. Stewart Minerva Neurosciences Inc. said Wednesday it decided to opt out of an agreement with Janssen Pharmaceutica NV for development of seltorexant for insomnia, avoiding… | July 1, 2020
   Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session  2020/06/05 13:05:00 Zacks Investment Research
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
   How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry  2020/06/02 13:00:00 Zacks Investment Research
Minerva Neurosciences (NERV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.
   Minerva Neurosciences (NERV) Looks Good: Stock Adds 8.4% in Session  2020/06/05 13:05:00 Zacks Investment Research
Minerva Neurosciences (NERV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
   How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry  2020/06/02 13:00:00 Zacks Investment Research
Minerva Neurosciences (NERV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas  2020/05/27 11:25:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) Catalent Inc (NYSE: CTLT ) ChemoCentryx Inc (NASDAQ: CCXI ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Cue Biopharma Inc (NASDAQ: CUE ) Evoke Pharma Inc (NASDAQ: EVOK ) Fate Therapeutics Inc (NASDAQ: FATE ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter  2020/05/13 11:40:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Acceleron Pharma Inc (NASDAQ: XLRN )(reacted to its first-quarter results) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioSig Technologies Inc (NASDAQ: BSGM ) BIO-TECHNE Corp (NASDAQ: TECH ) BioXcel Therapeutics Inc (NASDAQ: BTAI )(announced its first-quarter results) Black Diamond Therapeutics Inc (NASDAQ: BDTX )(reacted to its first-quarter results) ChemoCentryx Inc (NASDAQ: CCXI )(reacted to its first-quarter results) Cytokinetics, Inc. (NASDAQ: CYTK ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Cytosorbents Corp (NASDAQ: CTSO )(announced European approval for Cytosorb) Emergent Biosolutions Inc (NYSE: EBS ) Exelixis, Inc. (NASDAQ: EXEL ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ミネルバ・ニュ―ロサイエンシズ NERV Minerva Neurosciences Inc)

 twitter  (公式ツイッターやCEOツイッターなど)